IntegraGen, IFCT to Evaluate microRNA as Lung Cancer Biomarker | GenomeWeb

NEW YORK (GenomeWeb) – Molecular diagnostics firm IntegraGen announced that it is collaborating with the French Intergroup of Thoracic Oncology (IFCT), a network of lung cancer specialists, to investigate the potential of a specific microRNA as a biomarker for advanced non-small cell lung cancer.

Specifically, the partners will examine whether the expression of the miRNA, miR-31-3p, is correlated with patient outcomes associated with epidermal growth factor receptor (EGFR)-targeted therapies for lepidic adenocarcinomas of the lung.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.